Effects of intravenous famotidine on gastric acid secretion in patients undergoing cardiac surgery.

Author(s): Wagner BK, Amory DW, Majcher CM, DiFazio LT, Scott GE, Spotnitz AJ

Affiliation(s): Department of Pharmacy Practice and Administration, Rutgers College of Pharmacy, Piscataway, NJ, USA.

Publication date & source: 1995-04, Ann Pharmacother., 29(4):349-53.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVE: To determine the effects of cardiopulmonary bypass and famotidine on gastric acid secretion in adults undergoing cardiac surgery. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: University teaching hospital. PARTICIPANTS: Eighteen patients undergoing elective cardiac surgery with cardiopulmonary bypass. MAIN OUTCOME MEASURES: Famotidine 20 mg or NaCl 0.9% placebo was administered intravenously following induction of anesthesia and placement of a nasogastric pH probe. A second dose was given 12 hours after surgery in the intensive care unit. Gastric pH was measured continuously and gastric volume was measured every 4 hours for up to 24 hours after cardiopulmonary bypass. RESULTS: Following famotidine administration, pH increased by 43% within 45 minutes and remained above 5.5 throughout the study period (p < 0.05 vs placebo and baseline). The gastric pH did not increase, but remained above 4.0 in most patients in the placebo group for up to 12 hours after cardiopulmonary bypass. Gastric volumes were on average 24% lower in the famotidine group (p > 0.05). CONCLUSIONS: Gastric acid secretion is decreased during and for 12 hours after cardiopulmonary bypass. Perioperative administration of famotidine suppresses gastric secretion in cardiac surgery patients.